Essential Pharmaceuticals Announces the Release of Cell-Ess® Serum Replacement for Cell Culture
Essential Pharmaceuticals, a Ewing, NJ biotech company, announces Cell-Ess® is now available as a replacement for the Fetal Bovine Serum (FBS) that is commonly used in cell culture.
Ewing, NJ July 15, 2014 – Essential Pharmaceuticals LLC, announces the release of Cell-Ess® serum replacement for cell culture. Cell-Ess is a replacement for the Fetal Bovine Serum (FBS) that is commonly used in cell culture. The product is chemically defined, animal component free and delivers critical components that are needed for cell growth.
Cell-Ess enables researchers to eliminate FBS use in both basic research and bio-production of proteins or cells. Cell-Ess provides a greater level of performance, convenience and control not always attainable when using FBS. Some inherent limitations when using FBS in cell culture are that it is an animal product, containing viral and bacterial contaminants harmful to humans, isn’t consistent lot to lot, and requires special handling or processing before it can be used.
“By better duplicating biological processes, Cell-Ess will enable researchers to advance discovery by seeing more relevant results from the cell culture models they use today” says Allan Weber, CEO of Essential Pharmaceuticals. “It also increases product safety by providing a high performance, animal component free, alternative to FBS when used in bio-production to synthesize proteins.”
Cell culture enables scientists to conduct thousands of simultaneous experiments and understand cell behavior and metabolic processes without using humans or animals. FBS has been a critical component of the media that is used to culture cells. FBS contains hundreds of growth factors, hormones and plating factors that help cells grow. At one time it was most important to simply grow billions of cells for experiments. Now it is becoming more apparent that factors in FBS signal cells to perform in ways that are not the same as when those cells are in a tissue or organ. These cell signaling factors obscure the ability of scientists to elucidate metabolic pathways that lead to a healthy or disease state.
“At Essential Pharmaceuticals we aim to provide solutions to manage organs, tissues and individual cells for research purposes” says Allan Weber, CEO.
Essential Pharmaceuticals, LLC was established in 2006 and is best known for its role supporting the organ transplant market by providing the organ preservation solution, Custodiol HTK®. Custodiol HTK is indicated for perfusion and flushing of donor kidneys, liver, pancreas and heart prior to removal from the donor or immediately after removal from the donor. It is also the only organ preservation solution in the United States that is FDA approved for the perfusion and preservation of both abdominal and thoracic organs.
Cell-Ess is only the first of a series of planned “Ess” product releases this year. This launch will be followed by Cryo-Ess®, an animal component free and non-toxic, cell cryopreservation medium and Clin-Ess®, a non-toxic, animal component free transportation medium for tissue. Ess products are designed to help research scientists advance discovery in areas of drug development, cancer, autoimmune disease, metabolic disease, regenerative medicine, cell therapy and others.
For more information visit contact our corporate office: 609 323-7838. Email: Info@EssentialPharma.com.
About Essential Pharmaceuticals
Essential Pharmaceuticals, LCC, is based in Ewing, NJ, and provides transplant surgeons, medical researchers, and manufacturers new tools to bring performance, convenience, and control to enhance the advancement of basic research and drug discovery. Established in 2006, Essential Pharmaceuticals supports the preservation and growth of human systems—from the cell to the entire organ—through expanding its research and product development to further medical treatments for mankind.
Further information: EssentialPharma.com
Denise A. Weber
Princeton South Corporate Center
Ewing, NJ 08628